TG Therapeutics (NASDAQ:TGTX) Releases Earnings Results, Misses Expectations By $0.02 EPS

TG Therapeutics (NASDAQ:TGTX) posted its quarterly earnings results on Wednesday. The biopharmaceutical company reported ($0.07) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.02), Briefing.com reports. The company had revenue of $63.47 million during the quarter, compared to the consensus estimate of $54.60 million. TG Therapeutics had a return on equity of 12.89% and a net margin of 5.42%. The company’s revenue for the quarter was up 713.5% compared to the same quarter last year. During the same period last year, the firm posted ($0.28) EPS.

TG Therapeutics Price Performance

Shares of TGTX traded up $0.12 during mid-day trading on Thursday, reaching $16.00. 4,014,531 shares of the stock traded hands, compared to its average volume of 4,279,764. The firm has a fifty day moving average price of $15.13 and a 200 day moving average price of $14.33. The company has a market cap of $2.47 billion, a price-to-earnings ratio of 800.40 and a beta of 2.33. The company has a current ratio of 5.92, a quick ratio of 5.18 and a debt-to-equity ratio of 0.62. TG Therapeutics has a 1 year low of $6.46 and a 1 year high of $35.67.

Analyst Ratings Changes

A number of equities research analysts recently commented on the stock. B. Riley lifted their price target on shares of TG Therapeutics from $24.00 to $29.00 and gave the stock a “buy” rating in a report on Monday, February 5th. StockNews.com cut shares of TG Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, February 24th. LADENBURG THALM/SH SH boosted their target price on shares of TG Therapeutics from $39.00 to $40.00 and gave the company a “buy” rating in a report on Thursday. JPMorgan Chase & Co. reissued an “overweight” rating and set a $25.00 target price on shares of TG Therapeutics in a report on Thursday, April 18th. Finally, The Goldman Sachs Group boosted their target price on shares of TG Therapeutics from $12.00 to $13.00 and gave the company a “neutral” rating in a report on Thursday, February 29th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $29.17.

Insider Activity

In other news, Director Laurence N. Charney sold 22,000 shares of the business’s stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $15.97, for a total transaction of $351,340.00. Following the completion of the transaction, the director now directly owns 215,229 shares in the company, valued at approximately $3,437,207.13. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 9.20% of the company’s stock.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.